Mutation Analysis Lung Cancer | Univ.-Prof. Dr. med. Hans Bojar

UOMORPHIS
GmbH & Co. KG
European Institute for Molecular Oncology

Meisentalstr. 8
40764 Langenfeld

0171-7849894

Next event

05/22/2012 | 17.00 Chemotherapie ersparen durch genetische Tests
05/24/2012 | 19.30 Personalisierte Krebsbehandlung: Hoffnungen werden Wirklichk
06/06/2012 | 19.30 Personalisierte Krebsbehandlung: Hoffnungen werden Wirklichk

Mutation Analysis Lung Cancer

Lung cancer is a genetically heterogeneous disease. Novel targeted therapies focused on specific genetic alterations in individual tumors have opened up a promising new avenue for personalized cancer therapy.

mutationanalysis-lung-cancer1

Of utmost importance for the growth of non-small-cell lung cancer (NSCLC) is the MAPK/ERK signal transduction pathway and in addition the PIK3CA/AKT/mTOR pathway. Aberrant activations of these pathways lead to unrestricted tumor growth. Genetic basis of aberrant activations can be mutations (EGFR, KRAS, BRAF, PIK3CA) and a gene amplification (MEK). A gene fusion event (EML4-ALK) can also cause deregulated growth.

In view of the central role of theses pathways various targeted agents, focused on specific genetic modifications, have been developed.

Test pre-conditions

Formalin-fixed paraffin-embedded tissue is required. Minute tissue quantities (e. g. needle biopsies) are sufficient.

Test duration

Maximum test duration is 7 days.

Logistics

Formalin-fixed paraffin-embedded tumor tissue blocks routinely prepared by the local pathologists are used. These paraffin blocks are usually archived by the pathologist for 10 years. The paraffin embedded tissue is the property of the patient. Thus, the patient has the right of free disposal. On your written request (e-mail) we can take care of the tissue transfer.

Reference

http://www.ncbi.nlm.nih.gov/pubmed

http://www.ncbi.nlm.nih.gov/pubmed/20623207